Stocks to Watch: MiMedx Group, Nokia
29 Diciembre 2023 - 5:39PM
Noticias Dow Jones
By Ben Glickman
MiMedx Group said on Friday it received an FDA warning letter
related to the classification of its product Axiofill. The
regulator has reaffirmed that the company's treatment doesn't
qualify as a Section 361 product, meaning it likely requires
pre-market review. Shares fall 6.5% to $8.20 after-hours.
Nokia expects to miss its 2023 financial outlook as
license-renewal discussions stretch into 2024. The company expects
to miss guidance on net sales, comparable operating margin and free
cash flow, and can't provide preliminary financial results for the
quarter because the reporting period hasn't concluded. Shares fall
1.5% to $3.37 after-hours.
Write to Ben Glickman at ben.glickman@wsj.com
(END) Dow Jones Newswires
December 29, 2023 18:24 ET (23:24 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
Nokia (NYSE:NOK)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Nokia (NYSE:NOK)
Gráfica de Acción Histórica
De May 2023 a May 2024